Expert Interview
Discussing commercial use of Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay
Ticker(s): APLS, ALPMFInstitution: Duke
- Assistant Professor of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery at Duke.
- Manages 500 patients with geographic atrophy.
- Studies the biology, diagnosis and treatment of macular edema, and I am involved in basic laboratory science, ocular imaging analysis and clinical trials of new medications.
Describe your background and practice setting
Added By: wilson_adminHow many patients with GA do you manage? Has that number increased since the approval of Syfovre and Izervay?
Added By: wilson_adminWhat GA patients are eligible for treatment?
Added By: wilson_adminDo you have a preference between Izervay and Syfovre? If so, why?
Added By: wilson_adminWhat percent of patients do you prescribe each medication to?
Added By: wilson_adminWhich medication to you anticipate prescribing most often in the next 12 months?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
